Coming Soon

APVO436-5201: APVO436 Phase 1b/2 Study in Patients with Newly Diagnosed acute myeloid leukemia (AML).

We are looking for a dose of the APVO436 in combination with venetoclax and azacitidine that can be administered safely to participants who have been diagnosed with AML.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study will start enrolling soon.

North Carolina (Statewide)

Additional Study Information

Principal Investigator

Joshua Zeidner
Medicine-Hematology

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Leukemia)

IRB Number

24-3173

ClinicalTrials.gov

NCT06634394

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.